为临床医生解释图形卷积网络预测-一种可解释的AI方法来对阿尔茨海默氏症疾病进行分类
Sule Tekkesinoglu1, Sara Pudas2,3
1Department of Computing Science, Umeå University, Umeå, Sweden.
Frontiers in artificial intelligence
|January 23, 2024
概括
这项研究引入了一种用于预测阿尔茨海默病 (AD) 进展的图形卷积网络 (GCN) 的新解释方法. 该方法通过澄清患者数据如何影响诊断预测来增强信任和临床采用.
科学领域:
- 医疗信息学 医疗信息学
- 医疗保健中的机器学习
- 神经成像分析分析 神经成像分析
背景情况:
- 基于图形的表示在医学中越来越多地用于模拟患者关系和预测疾病.
- 图形卷积网络 (GCN) 可以分析神经认知,遗传和脑缩数据中的复杂模式,用于认知状态预测.
- 阐明GCN预测对于临床采用和医生对诊断决策支持系统的信任至关重要.
研究的目的:
- 引入基于分解的解释方法,用于使用GCNs进行个体患者分类.
- 了解各种特征和关系对诊断预测的贡献.
- 提高GCN模型在医疗应用中的可解释性和可靠性.
主要方法:
- 在阿尔茨海默病神经成像计划 (ADNI) 数据库上使用GCN模型来预测认知状态 (正常认知,轻度认知障碍,阿尔茨海默病).
- 开发了基于分解的方法来分析基于输入值变化的输出变化,评估特征和边缘影响.
- 通过选择性地沉默边缘来研究关系数据,以获得邻居级别的解释.
主要成果:
- 解释方法在微小的输入变化下表现出稳定性,特别是在0.80.0以上的边缘重量方面.
- 与SHAP值的比较分析显示了可比结果,计算时间显著减少.
- 一项对11位领域专家的调查显示,71%的人证实了解释的正确性,对可理解性的评分高于六分之一.
结论:
- 拟议的解释方法为认知状态的GCN预测提供了稳定和可理解的见解.
- 该方法为现有方法 (如SHAP) 提供了一个计算效率高的替代方案.
- 解决诸如GCN依赖人口统计数据等局限性问题,将进一步促进临床采用,并建立医生信任.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.9K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
相关概念视频
Alzheimer's Disease: Overview
487
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
487
Alzheimer's Disease: Treatment
193
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
193
